Greg Zante
Chief Financial Officer · 1 filing · Latest: Jul 28, 2026
Viking Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
VKTX | Greg Zante | Chief Financial Officer | Jul 29, 2026 | Sale | $33.47 | 21,217 | $710.1K | 212,204 | |
VKTX | GREG ZANTE | — | Jul 29, 2026 | Proposed Sale | $33.47 | 21,217 | $710.1K | — | |
VKTX | GREG ZANTE | — | Jan 5, 2026 | Proposed Sale | $32.98 | 57,661 | $1.9M | — | |
VKTX | GREG ZANTE | — | Oct 28, 2025 | Proposed Sale | $35.01 | 6,185 | $216.5K | — | |
VKTX | GREG ZANTE | — | Jul 3, 2025 | Proposed Sale | $27.76 | 4,266 | $118.4K | — | |
VKTX | GREG ZANTE | — | Jan 6, 2025 | Proposed Sale | $42.75 | 50,309 | $2.2M | — | |
VKTX | GREG ZANTE | — | Oct 28, 2024 | Proposed Sale | $78.03 | 131,687 | $10.3M | — |